As treatment options continue to expand across numerous disease settings, new practice guidelines were released by the Society for Immunotherapy of Cancer (SITC) on the use of immunotherapy in the treatment of lymphoma.1 The guidelines, published in the Journal for ImmunoTherapy of Cancer, are intended to provide clinicians with the most current thinking on how experts can integrate immunotherapy into lymphoma treatment.
“Practicing clinicians have to take care of so many types of cancer, whereas in the old days there were common therapies across the board,” Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, explained in an interview with CancerNetwork®. “Now, the therapies are so much better individualized that [it can be] difficult for practicing community oncologists to stay abreast of every update.”
“Advances in…
